Ustekinumab as induction and maintenance therapy for Crohn's disease

Nursing and Health Professions

• Patient 100%
• Crohn Disease 100%
• Maintenance Therapy 100%
• Placebo 37%
• Combination Therapy 18%
• Remission 18%
• Crohn Disease Activity Index 18%
• Inpatient 12%
• Hospital Service 12%
• Dose 12%
• Side Effect 12%
• Intravenous Drug Administration 6%
• Adverse Event 6%
• Body Weight 6%
• Injection 6%
• Group Therapy 6%
• Tumor Necrosis Factor 6%
• Maintenance Drug Dose 6%
• Monoclonal Antibody 6%
• Interleukin 12 6%

Medicine and Dentistry

• Crohn's Disease 100%
• Maintenance Therapy 100%
• Placebo 37%
• Combination Therapy 18%
• Spontaneous Remission 18%
• Side Effect 12%
• Adverse Event 6%
• Group Therapy 6%
• Injection 6%
• Tumor Necrosis Factor 6%
• Body Weight 6%
• Antagonist 6%
• Monoclonal Antibody 6%
• Interleukin 23 6%
• Intravenous Drug Administration 6%